22 assets in Central Nervous System Disorder

Therapeutic assets addressing Central Nervous System Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
3-N-BUTYLPHTHALIDE Central Nervous System Disorder	Qianfoshan Hospital	P4	BB (65)
Live Combined Bifidobacterium Central Nervous System Disorder	Beijing Friendship Hospital	P4	BB (65)
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules Central Nervous System Disorder	Beijing Friendship Hospital	P4	BB (65)
Donanemab Central Nervous System Disorder	Eli Lilly and Company	P3	BB (64)
Dexasone Central Nervous System Disorder	Eli Lilly and Company	P3	B (60)
Tenecteplase Central Nervous System Disorder	University of Melbourne	P2/3	B (57)
Retigabine Central Nervous System Disorder	Xenon Pharmaceuticals Inc.	P3	CCC (54)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Central Nervous System Disorder	PharmaTher Inc.	P2	CCC (53)
Apsolol Central Nervous System Disorder	Tianjin Medical University General Hospital	P2	CCC (53)
Ceftriaxone Central Nervous System Disorder	Tianjin Medical University General Hospital	P2	CCC (53)
Midazolam Central Nervous System Disorder	PharmaTher Inc.	P2	CCC (53)
Silevertinib Central Nervous System Disorder	Black Diamond Therapeutics, Inc.	P2	CCC (53)
Pegipanermin Central Nervous System Disorder	Inmune Bio, Inc.	P2	CCC (48)
Pembrolizumab Central Nervous System Disorder	Reva Basho	P1/2	CCC (48)
Trastuzumab Central Nervous System Disorder	Reva Basho	P1/2	CCC (48)
Tucatinib Central Nervous System Disorder	Reva Basho	P1/2	CCC (48)
Abemaciclib Central Nervous System Disorder	Stemline Therapeutics, Inc.	P1/2	CC (47)
Elacestrant Central Nervous System Disorder	Stemline Therapeutics, Inc.	P1/2	CC (47)
G 207 Central Nervous System Disorder	M.D. Anderson Cancer Center	P1	CC (43)
Adrenomedullin Central Nervous System Disorder	Danish Headache Center	N/A	D (30)
Amylin Central Nervous System Disorder	Danish Headache Center	N/A	D (30)
Rvp-001 Central Nervous System Disorder	Reveal Pharmaceuticals Inc.	P2	NR ()